CD33-targeted chimeric antigen receptor-modified t cells for treating cd33-positive malignancies
By using CD33-targeted chimeric antigen receptor-modified T cells, the low cure rate of AML treatment has been solved, achieving specific killing and therapeutic effects on CD33-positive cells, significantly reducing tumor burden and prolonging survival time.
Patent Information
- Application Number
- CN202080047912.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2019-05-31
- Filing Date
- 2020-06-01
- Publication Date
- 2025-10-17
- Estimated Expiration
- 2040-06-01
AI Technical Summary
In the current technology, the cure rate of acute myeloid leukemia (AML) is low, especially for patients with relapsed or refractory AML, there is a lack of effective treatments, and CD33 positive cells are widely expressed in leukemia and other cancers, but there is a lack of specific treatments.
T cells modified with CD33-targeting chimeric antigen receptor (CAR) are transduced by nucleic acid molecules encoding specific amino acid sequences and combined with hypomethylating agents such as decitabine to treat CD33-positive cells, including local or systemic administration of CD33-expressing cancerous T cells.
It achieves specific killing of CD33-positive leukemia and other cancers, significantly reduces tumor burden and prolongs patient survival time, reduces myeloid-derived suppressor cells, and improves treatment efficacy.